Podium to Practice: EHA 2025 – Multiple Myeloma: MAGNETISMM-6 PART 1

Podium to Practice: EHA 2025 – Multiple Myeloma: MAGNETISMM-6 PART 1

Podium to Practice: EHA 2025
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Donna Reece

Icon Chair Speaker

Speakers

Dr. Irwin Sandhu

Dr. Maria Victoria Mateos Manteca

Studies / Trials Discussed

S206 – ELRANATAMAB IN COMBINATION WITH DARATUMUMAB AND LENALIDOMIDE (EDR) IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) NOT ELIGIBLE FOR TRANSPLANT: INITIAL RESULTS FROM MAGNETISMM-6 PART 1

Studies/trials discussed:

S206 – ELRANATAMAB IN COMBINATION WITH DARATUMUMAB AND LENALIDOMIDE (EDR) IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) NOT ELIGIBLE FOR TRANSPLANT: INITIAL RESULTS FROM MAGNETISMM-6 PART 1
Tagged